Overview

Webcast Q4 2009 Poniard Pharmaceuticals Earnings Conference Call (Replay) 03/08/10 at 8:30 a.m. ET

Q4 2009 Poniard Pharmaceuticals Earnings Conference Call Monday, March 8, 2010 8:30 a.m. ET   Webcast Presentation Help   Click here for webcast Add to Calendar Help  Click here to add this event to your calendar

Stock Quote PARD (Common Stock) Exchange NASDAQ (US Dollar) Price $1.55 Change (%)   0.01 (0.64%) Volume 2,906,400 Data as of 03/10/10 4:00 p.m. ET Minimum 20 minute delay Refresh quote

What's New Date Title 02/09/10   Biotechnology Industry Organization CEO & Investor Conference Receive E-mail Alerts Sign up to receive e-mail alerts whenever Poniard Pharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.

Date Title     03/08/10 Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results Conference Call Today at 8:30 a.m. Eastern Time -SOUTH SAN FRANCISCO, Calif., March 8, 2010 /PRNewswire via COMTEX/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009. "Picoplatin's value proposition rests on establishing it as the preferred platinum," said Ronald A. Martell, chief executive officer of Poniard. "With nearly 1,100 patients ...    03/05/10 Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium SOUTH SAN FRANCISCO, Calif., March 5, 2010 /PRNewswire via COMTEX/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today a...    03/01/10 Poniard Pharmaceuticals to Host Fourth Quarter and Year End 2009 Financial Results Conference Call on March 8 SOUTH SAN FRANCISCO, Calif., March 1, 2010 /PRNewswire via COMTEX/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it will hold a conference call on Monday, March 8, 2010 to discuss the Company's fourth quarter and fiscal year 2009 financial results and provide a corporate update. Ronald A. Martell, chief executive officer, Michael S. Perry, president and chief medical officer, and Greg Weaver, senior vic...    02/23/10 Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility SOUTH SAN FRANCISCO, Calif., Feb 23, 2010 /PRNewswire via COMTEX/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it has entered into a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Commerce Court Small Cap Value Fund, Ltd. over an approximately 18-month period. Poniard is not obligated to utilize any of the facility and remains free to en...

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.